These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 2383564)
1. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Donahue BA; Augot M; Bellon SF; Treiber DK; Toney JH; Lippard SJ; Essigmann JM Biochemistry; 1990 Jun; 29(24):5872-80. PubMed ID: 2383564 [TBL] [Abstract][Full Text] [Related]
3. RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II). Corda Y; Anin MF; Leng M; Job D Biochemistry; 1992 Feb; 31(7):1904-8. PubMed ID: 1536834 [TBL] [Abstract][Full Text] [Related]
4. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins. Kaspárková J; Brabec V Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982 [TBL] [Abstract][Full Text] [Related]
5. Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3)2(N3-cytosine)Cl]+. Bellon SF; Lippard SJ Biophys Chem; 1990 Apr; 35(2-3):179-88. PubMed ID: 2397272 [TBL] [Abstract][Full Text] [Related]
6. Chemical and biological studies of the major DNA adduct of cis-diamminedichloroplatinum(II), cis-[Pt(NH3)2(d(GpG]], built into a specific site in a viral genome. Naser LJ; Pinto AL; Lippard SJ; Essigmann JM Biochemistry; 1988 Jun; 27(12):4357-67. PubMed ID: 3166983 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II). Sundquist WI; Lippard SJ; Stollar BD Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8225-9. PubMed ID: 2446320 [TBL] [Abstract][Full Text] [Related]
8. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Bellon SF; Coleman JH; Lippard SJ Biochemistry; 1991 Aug; 30(32):8026-35. PubMed ID: 1868076 [TBL] [Abstract][Full Text] [Related]
9. Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. Wei M; Cohen SM; Silverman AP; Lippard SJ J Biol Chem; 2001 Oct; 276(42):38774-80. PubMed ID: 11514569 [TBL] [Abstract][Full Text] [Related]
10. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). Yarema KJ; Lippard SJ; Essigmann JM Nucleic Acids Res; 1995 Oct; 23(20):4066-72. PubMed ID: 7479066 [TBL] [Abstract][Full Text] [Related]
11. Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA. Payet D; Gaucheron F; Sip M; Leng M Nucleic Acids Res; 1993 Dec; 21(25):5846-51. PubMed ID: 8290343 [TBL] [Abstract][Full Text] [Related]
12. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057 [TBL] [Abstract][Full Text] [Related]
13. Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents. Hollis LS; Sundquist WI; Burstyn JN; Heiger-Bernays WJ; Bellon SF; Ahmed KJ; Amundsen AR; Stern EW; Lippard SJ Cancer Res; 1991 Apr; 51(7):1866-75. PubMed ID: 2004370 [TBL] [Abstract][Full Text] [Related]
14. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126 [TBL] [Abstract][Full Text] [Related]
15. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins. Kane SA; Lippard SJ Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559 [TBL] [Abstract][Full Text] [Related]
16. The new antitumor compound, cis-[Pt(NH3)2(4-methylpyridine)Cl]Cl, does not form N7,N7-d(GpG) chelates with DNA. An unexpected preference for platinum binding at the 5'G in d(GpG). Lempers EL; Bloemink MJ; Brouwer J; Kidani Y; Reedijk J J Inorg Biochem; 1990 Sep; 40(1):23-35. PubMed ID: 2283508 [TBL] [Abstract][Full Text] [Related]
17. A 1,2-d(GpG) cisplatin intrastrand cross-link influences the rotational and translational setting of DNA in nucleosomes. Ober M; Lippard SJ J Am Chem Soc; 2008 Mar; 130(9):2851-61. PubMed ID: 18269283 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Treiber DK; Zhai X; Jantzen HM; Essigmann JM Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5672-6. PubMed ID: 8202546 [TBL] [Abstract][Full Text] [Related]
19. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques. Plooy AC; Fichtinger-Schepman AM; Schutte HH; van Dijk M; Lohman PH Carcinogenesis; 1985 Apr; 6(4):561-6. PubMed ID: 4039227 [TBL] [Abstract][Full Text] [Related]
20. Transcription inhibition by platinum-DNA cross-links in live mammalian cells. Ang WH; Myint M; Lippard SJ J Am Chem Soc; 2010 Jun; 132(21):7429-35. PubMed ID: 20443565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]